CTIS2022-501086-41-00进行中（未招募）1 期
ong-Term Follow-Up (LTFU) for Gene Therapy of Leukocyte Adhesion Deficiency-I (LAD-I).Phase I/II clinical study to evaluate the safety and efficacy of the infusion of autologous hematopoietic stem cells transduced with a lentiviral vector encoding the ITGB2 gene - RP-L201-0121-LTF
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 9
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 0 至 64（—）
- 性别
- All
入选标准
- •Patient was enrolled in the Phase I/II Study RP-L201-0318., Patient received an autologous infusion of CD34+ hematopoietic stem cells modified with a lentiviral vector containing the ITGB2 gene, encoding for the human CD18 receptor in the parent Study RP-L201-0318., Patient is willing and able to adhere to the study visit schedule and other protocol requirements., Patient provided written informed consent and, as applicable, assent to participate in the current study in accordance with current regulatory requirements.
排除标准
- •There are no criteria for exclusion in this study.
研究者
相似试验
招募中
1 期
ong-Term Follow-Up (LTFU) for Gene Therapy of Pyruvate Kinase Deficiency (PKD): A Phase I Clinical Trial to Evaluate the Safety of the Infusion of Autologous CD34+ Cells Transduced with a Lentiviral Vector Carrying the Codon Optimized Red Cell Pyruvate Kinase (coRPK) Gene in Adult and Pediatric Subjects with PKDPyruvate kinase deficiencyCTIS2022-501526-38-00Rocket Pharmaceuticals Inc.5
进行中（未招募）
不适用
Long-Term Follow-Up (LTFU) for Gene Therapy of Leukocyte Adhesion Deficiency-I (LAD-I)Leukocyte Adhesion DeficiencyNCT06282432Rocket Pharmaceuticals Inc.9
招募中
不适用
ong-term observational study of Gene Therapy for AADC deficiencyAromatic L-amino acid decarboxylase deficiencyJPRN-jRCT2033220245Yamagata Takanori1
招募中
Unknown
ong-term observational study of Gene Therapy for Parkinson's diseaseParkinson's diseaseJPRN-jRCT2033220367akajima Takeshi12
已完成
不适用
Gene Therapy for Patients With Leukocyte Adherence Deficiency (Follow-Up of Phase 1 Trial)Leukocyte Adhesion Deficiency SyndromeNCT00023010National Cancer Institute (NCI)2